OXURION (EBR:OXUR) | WebDisclosure

PRESS RELEASE

published on 08/07/2025 at 18:00, 7 months 16 days ago

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
Oxurion beendet präklinisches Forschungsprogramm zur Entwicklung neuer Therapieziele für altersbedingte Makuladegeneration (GA) und fokussiert auf CRO-Aktivitäten und Profitabilität. Integrierte Datenexpertise und externe Expansion im Fokus

Profitabilität Oxurion Präklinisches Forschungsprogramm GA CRO-Aktivitäten
PRESS RELEASE

published on 08/07/2025 at 18:00, 7 months 16 days ago

Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies

Clinical Research Biopharmaceutical UBS Group AG Oxurion NV Transparency Notifications
PRESS RELEASE

published on 08/07/2025 at 18:00, 7 months 16 days ago

Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgevingen van UBS Group AG over aandelentransacties conform Belgische wetgeving. Oxurion, biofarmaceutisch bedrijf in Leuven, België, integreert innovatie en klinisch onderzoekstechnologieën

Transparantiekennisgevingen UBS Group AG Oxurion NV Biofarmaceutisch Belgische Wetgeving
BRIEF

published on 08/06/2025 at 18:05, 7 months 17 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
BRIEF

published on 08/06/2025 at 18:05, 7 months 17 days ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE

published on 08/06/2025 at 18:00, 7 months 17 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen over aandelentransacties en stimuleert therapeutische innovatie in biofarmaceutica. Zie voor meer informatie www.oxurion.com

Aandelentransacties Transparantiekennisgevingen Oxurion NV Therapeutische Innovatie Biofarmaceutica
PRESS RELEASE

published on 08/06/2025 at 18:00, 7 months 17 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding changes in shareholding from Atlas Special Opportunities II, LLC as per Belgian Transparency legislation. Company combines therapeutic innovation with technology for new treatments

Clinical Research Shareholding Changes Oxurion NV Therapeutic Innovation Transparency Notifications
BRIEF

published on 08/04/2025 at 18:05, 7 months 19 days ago

Oxurion Sécurise 30 M EUR Pour Diversification en Actifs Numériques

Investissement Financement Biopharmaceutique Cryptomonnaies Oxurion
BRIEF

published on 08/04/2025 at 18:05, 7 months 19 days ago

Oxurion Secures EUR 30M for Diversification into Digital Assets

Funding Investment Cryptocurrencies Biopharmaceuticals Oxurion
PRESS RELEASE

published on 08/04/2025 at 18:00, 7 months 19 days ago

Oxurion obtient une offre de financement revue à la hausse à 30 M EUR pour lancer la diversification de sa trésorerie en actifs numériques
Oxurion NV reçoit une offre de financement de 30 millions d'euros d'Atlas Special Opportunities pour investir dans Bitcoin et Ethereum. Objectif de diversification de la trésorerie

Financement Bitcoin Ethereum Oxurion NV 30 Millions D'euros

Published on 03/24/2026 at 08:01, 31 minutes ago

Star Copper Confirms Copper Creek Mineralization
Published on 03/24/2026 at 07:00, 1 hour 32 minutes ago

Panther Minerals Earns In Under Rubidium Ridge Project Option
Published on 03/24/2026 at 07:00, 1 hour 32 minutes ago

Panther Completes Acquisition of Rubidium Ridge Project
Published on 03/24/2026 at 00:55, 7 hours 37 minutes ago

BTU Closes Oversubscribed Financing
Published on 03/23/2026 at 22:40, 9 hours 52 minutes ago

Troubadour Announces Withdrawal of Non-Brokered Private Placements

View all ACCESSWIRE

Published on 03/24/2026 at 08:00, 32 minutes ago

Transaction in Own Shares
Published on 03/24/2026 at 07:30, 1 hour 2 minutes ago

Drägerwerk AG & Co. KGaA: Dräger with good order development, record net sales and significant increase in net profit in fiscal year 2025 – third dividend increase in a row
Published on 03/24/2026 at 07:23, 1 hour 8 minutes ago

INDUS confirms a solid financial year 2025 – Proposed dividend of EUR 1.30 exceeds previous year
Published on 03/24/2026 at 07:00, 1 hour 31 minutes ago

After strong fourth quarter, INFICON closes 2025 at record sales level
Published on 03/24/2026 at 07:00, 1 hour 31 minutes ago

Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved

View all EQS

Published on 03/24/2026 at 07:45, 47 minutes ago

François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 47 minutes ago

La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 1 hour 2 minutes ago

Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/24/2026 at 07:30, 1 hour 2 minutes ago

Gimv verzekert zich van een nieuwe Revolving Credit Facility van EUR 400 miljoen ter ondersteuning van de versnelde groeiambities
Published on 03/23/2026 at 19:08, 13 hours 23 minutes ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026

View all LES ECHOS COMFI WIRE

News